Lifileucel Demonstrates Long-Term Efficacy and Survival Benefit in Advanced, Pretreated Melanoma
Source: OncLive, January 2024
Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.
The autologous tumor infiltrating lymphocyte (TIL) cell therapy lifileucel (LN-144) demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors, supporting its use as a viable potential treatment option in this population, according to long-term findings from the phase 2 C-144-01 trial (NCT02360579) presented at the 2023 ESMO Immuno-Oncology Congress.
After 4 years of follow-up, patients from cohorts 2 and 4 of the study (n = 153) experienced a substantial reduction in tumor burden from baseline, with an objective response rate of 31.4% per independent review committee (IRC) assessment. The median time to best response for those who achieved a partial response or better was 1.5 months (range, 1.3-30.4). The longest duration of IRC-assessed response was ongoing at 55.8 months. Moreover, 4 patients converted to a complete response more than 1 year after treatment with lifileucel.